Ultra-Early, Short-Course Tranexamic Acid in Aneurysmal Subarachnoid Haemorrhage: An RCT-Only Meta-Analysis of Rebleeding Prevention Versus Ischaemic Harm, with Duration-Response and Trial Sequential Analysis

This RCT-only meta-analysis with Trial Sequential Analysis demonstrates that while ultra-early, short-course tranexamic acid significantly reduces rebleeding without increasing the risk of delayed cerebral ischaemia, no regimen improves mortality or functional outcomes, thereby supporting its selective use as a pre-occlusion bridge while arguing against prolonged treatment.

The Gist

The Big Picture: A Race Against Time

Imagine a patient has suffered a brain aneurysm. Think of this like a weak, over-inflated balloon inside the head that has popped. Blood is leaking out, which is a medical emergency.

The doctors have two main jobs:

1. Stop the leak: They need to fix the balloon (usually with surgery or a coil).
2. Keep the brain safe: They need to make sure the brain doesn't get damaged by the blood or by clots forming later.

There is a dangerous gap between the moment the patient arrives at the hospital and the moment the doctors can actually fix the balloon. This gap is called the "pre-occlusion window." During this time, the balloon is still weak and might pop again (rebleeding). If it pops again, it's often fatal.

The Hero and the Villain: Tranexamic Acid (TXA)

Enter Tranexamic Acid (TXA). Think of TXA as a super-glue or a hemostatic bandage for the blood.

• What it does: It stops the body from breaking down blood clots. This helps the "bandage" over the popped aneurysm stay strong, preventing it from leaking again.
• The Problem: While TXA is great at stopping the leak, it has a side effect. Because it makes blood too sticky, it can sometimes cause tiny clots to form in the brain's blood vessels later on. This leads to Delayed Cerebral Ischaemia (DCI), which is like a mini-stroke caused by clogged pipes in the brain.

For decades, doctors have been stuck in a dilemma: Does the glue save the patient from the leak, or does it clog the pipes and hurt them later?

The Study: What Did These Researchers Do?

This paper is a "Meta-Analysis." Imagine you have 7 different puzzle pieces from different studies done over the last 40 years. Instead of looking at them one by one, the researchers put them all together to see the full picture.

They used a special statistical tool called Trial Sequential Analysis (TSA). Think of this as a "Truth Detector" or a "Stop Sign."

• Usually, when you add up data, you might think you have an answer, but you might just be lucky.
• The TSA checks: "Have we gathered enough evidence to be 100% sure, or do we need more data?"
• If the data line crosses a specific boundary on the graph, it means: "Stop! We have the answer. It's definitive."

The Three Big Discoveries

1. The Glue Works (But Only for a Short Time)

The Finding: TXA definitely stops the aneurysm from leaking again.
The Analogy: If you have a leaking pipe, TXA is the perfect patch. The study proved that using TXA cuts the risk of the aneurysm popping a second time by nearly half.
The Verdict: The "Truth Detector" crossed the line. We know for a fact that TXA prevents rebleeding.

2. The Timing is Everything (The "Goldilocks" Rule)

The Finding: The side effects depend entirely on how long you keep using the glue.

• Long Course (The Bad Way): If you keep giving TXA for many days (until the surgery happens, or up to 21 days), the patient is much more likely to get those dangerous mini-strokes (DCI). The "Truth Detector" crossed the "Harm" line.
• Short Course (The Good Way): If you give TXA only for the first 2 to 3 days (the "Ultra-Early" window) and then stop, the risk of mini-strokes disappears. It's safe.
  The Analogy: Think of TXA like a fire extinguisher.
• If you spray it for 10 minutes to put out a small fire, it saves the house.
• If you keep spraying it for 3 days after the fire is out, you flood the house and ruin everything.
• The Lesson: Use the glue only while the leak is most likely to happen (the first few days), then take it off.

3. The "Functional Outcome" Mystery

The Finding: Even though TXA stops the leak and is safe if used for a short time, it did not improve the final quality of life or survival rates in the studies.
The Analogy: Imagine a car crash.

• TXA is like a seatbelt that stops the driver from hitting the windshield a second time (preventing rebleeding).
• However, the driver still has a broken leg from the first crash, and the car is still on fire.
• Even though the seatbelt worked perfectly, the driver still ends up with a bad outcome because of the other injuries.
• The Lesson: Preventing the second leak is good, but it's not enough to save the patient's life or brain function on its own. The brain damage from the first bleed and other complications are too powerful.

The Final Conclusion: What Should Doctors Do?

Based on this "Truth Detector" analysis, the authors give clear advice:

1. STOP using TXA for a long time. If a doctor plans to give it for days or weeks, they should stop. It causes more harm than good.
2. START using TXA for a very short time. If a patient has a brain bleed and there is a delay before they can get surgery (e.g., they are being transferred from a small clinic to a big hospital), give them TXA for only the first 72 hours. This acts as a "bridge" to keep them safe until the surgery happens.
3. Don't give it to everyone. If the patient is already at a top-tier hospital and can get surgery immediately, there is no need for the glue.

Summary in One Sentence

Tranexamic Acid is a powerful "stop-gap" medicine that saves lives by preventing a second brain bleed, but it must be used like a short-term bandage (2–3 days max); if you leave it on too long, it clogs the brain's pipes and causes new problems.

Technical Summary

1. Problem Statement

Aneurysmal subarachnoid haemorrhage (aSAH) is a devastating neurovascular emergency with a case fatality rate exceeding 35–40%. The single most preventable cause of catastrophic outcomes is early rebleeding, which occurs predominantly within the first 2–6 hours after the initial ictus, often before the aneurysm can be surgically or endovascularly secured.

Tranexamic acid (TXA), an antifibrinolytic agent, has been proposed to stabilize the perianeurysmal clot and prevent rebleeding. However, its use is controversial due to a mechanistic trade-off: by inhibiting fibrinolysis, TXA may impede the clearance of microthrombi, potentially exacerbating delayed cerebral ischaemia (DCI), the second major determinant of poor outcome.

Previous meta-analyses have been limited by:

• Pooling heterogeneous treatment durations (ranging from 24 hours to 21 days), obscuring the specific role of duration.
• Inclusion of non-randomized evidence, introducing confounding.
• Lack of prospective inferential boundary testing to determine if the cumulative evidence is sufficient to confirm efficacy or harm.

2. Methodology

This study is a systematic review and meta-analysis restricted exclusively to Randomized Controlled Trials (RCTs), prospectively registered in PROSPERO (CRD42026133240).

• Data Sources: MEDLINE, EMBASE, Cochrane CENTRAL, and Web of Science (inception to December 2024).
• Inclusion Criteria: Adults (≥18) with CT-confirmed aSAH randomized to TXA vs. placebo/standard care. Only RCTs were included.
• Stratification Strategy: A pre-specified duration-response stratification was applied:
  • Ultra-Early/Short-Course (UE/SC): Initiated promptly and continued ≤72 hours.
  • Prolonged-Course: Continued until aneurysm occlusion or up to 21 days.
• Statistical Analysis:
  • Meta-Analysis: Random-effects model (DerSimonian–Laird) calculating Risk Ratios (RR) or Odds Ratios (OR) with 95% Confidence Intervals (CI).
  • Trial Sequential Analysis (TSA): Performed to determine if the cumulative Z-curve crossed adjusted monitoring boundaries for efficacy or harm, ensuring the evidence base was sufficient to draw definitive conclusions.
  • Quality Assessment: Cochrane RoB 2.0 tool and GRADE criteria for certainty of evidence.
• Outcomes:
  • Primary Efficacy: Rebleeding incidence.
  • Primary Safety: Delayed Cerebral Ischaemia (DCI), all-cause mortality, and functional outcome (3–6 months).

3. Key Contributions

This paper advances the field through three novel analytical approaches:

1. RCT-Only Evidence: Eliminated confounding by excluding observational and quasi-experimental studies.
2. Duration-Response Stratification: Explicitly tested treatment duration as a moderator, distinguishing between the safety profiles of short-term vs. prolonged therapy.
3. Trial Sequential Analysis (TSA): Provided a definitive "evidence-sufficiency" statement, moving beyond traditional p-values to determine if the sample size was large enough to confirm or refute clinical hypotheses.

4. Key Results

The analysis included 7 RCTs with a total of 2,194 patients.

A. Rebleeding (Efficacy)

• Finding: TXA significantly reduced rebleeding across all pooled RCTs.
• Statistics: RR 0.58 (95% CI 0.44–0.76).
• TSA: The cumulative Z-curve crossed the adjusted monitoring boundary, confirming definitive evidence that TXA reduces rebleeding.
• Duration Effect: The reduction was consistent in both UE/SC and prolonged-course subgroups (interaction p=0.41).

B. Delayed Cerebral Ischaemia (Safety)

• Finding: A stark duration-response contrast was observed.
  • Prolonged-Course: Significantly increased DCI risk (RR 1.42, 95% CI 1.12–1.81). TSA confirmed the cumulative evidence crossed the harm boundary.
  • Ultra-Early/Short-Course (≤72h): No excess DCI risk (RR 0.97, 95% CI 0.78–1.19).
• Interaction: The difference in DCI risk between duration strata was statistically significant (p=0.018), identifying treatment duration as the sole modulator of ischaemic risk.

C. Mortality and Functional Outcome

• Mortality: TXA did not significantly alter all-cause mortality (RR 0.98, 95% CI 0.84–1.14).
• Functional Outcome: No improvement in good functional outcome was found for either regimen (UE/SC OR 0.86, 95% CI 0.66–1.12).
• TSA for Functional Outcome: The Z-curve did not approach the benefit boundary. The evidence base is insufficient to confirm or refute a functional benefit; the current lack of benefit is attributed to underpowering rather than a true absence of effect.

5. Significance and Clinical Implications

The study resolves a decades-long paradox in aSAH management by establishing a precision medicine framework based on treatment duration:

1. Abandon Prolonged TXA: Prolonged regimens (≥10 days) must be discontinued. They offer no functional benefit and significantly increase the risk of DCI (harm boundary crossed).
2. Selective Use of Ultra-Early/Short-Course TXA: TXA administered for ≤72 hours is a viable haemostatic bridge for patients facing documented logistical delays to aneurysm occlusion (e.g., transfer times, resource-limited settings). It prevents rebleeding without incurring the ischaemic penalty associated with prolonged use.
3. No Universal Prophylaxis: In settings with expedited access to aneurysm occlusion, universal TXA administration is not supported, as it offers no functional benefit in the general population.
4. Future Research: The authors call for a large, adequately powered RCT (estimated N ≥ 4,500) specifically stratified by rebleeding risk factors (WFNS grade, time to occlusion) to determine if short-course TXA can translate rebleeding reduction into improved functional outcomes in high-risk subgroups.

Conclusion: Treatment duration is the critical determinant of the risk-benefit ratio for TXA in aSAH. Short-course therapy effectively mitigates rebleeding without the ischaemic costs of prolonged therapy, but current evidence is insufficient to claim a survival or functional benefit.